X

Clinical Trials

Contact Us

Colon

EAY191-E4 **11/30/23: EAY191-E4 is nearing the completion of its first stage of accrual, and no additional treatment assignments will be processed** **If biopsy needed, TBD at MBMC**

ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors


URCC 22063

Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia (LOTUS-CC)


EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice


ALLIANCE A212102 **AT MBMC ONLY** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**

Blinded Reference Set For Multicancer Early Detection Blood Tests


URCC 19075 **MBMC ONLY**

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)


URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting


NCI 10323

Cancer Moonshot Biobank Research Protocol


NSABP C-14 / CORRECT-MRD II

Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease


A221805 **EFFECTIVE 3/31/23, at 7am CST, the Phase II portion of the study will permanently close to new patient accrual. Information regarding the status of the Phase III component will be sent upon completion of the Phase II analyses. If the analysis is positive, a reactivation notice will be distributed at the time A221805 opens to Phase III enrollment.**

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study


NRG-GI005 **Temporarily Suspended Effective 4 p.m. (CST) 7/5/23**

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)